Atjaunināt sīkdatņu piekrišanu

Early Vascular Aging (EVA): New Directions in Cardiovascular Protection [Hardback]

Edited by (Senior Professor, Cardiovascular Research, consultant, Department of Clinical Sciences, Lund University, Sweden), Edited by (Emeritus Professor of Ph), Edited by (Professor, University of Southern Denmark and Odense University Hospital, Odense C, Denmark)
  • Formāts: Hardback, 376 pages, height x width: 276x216 mm, weight: 1290 g
  • Izdošanas datums: 06-Aug-2015
  • Izdevniecība: Academic Press Inc
  • ISBN-10: 0128013877
  • ISBN-13: 9780128013878
Citas grāmatas par šo tēmu:
  • Hardback
  • Cena: 145,75 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
Early Vascular Aging (EVA): New Directions in Cardiovascular ProtectionPalielināt
  • Formāts: Hardback, 376 pages, height x width: 276x216 mm, weight: 1290 g
  • Izdošanas datums: 06-Aug-2015
  • Izdevniecība: Academic Press Inc
  • ISBN-10: 0128013877
  • ISBN-13: 9780128013878
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9780128013878.html
Keywords:
Early Vascular Aging (EVA): New Directions in Cardiovascular Protection brings together the last decade of research related to the characterization of EVA, as well as the predictive power of pulse wave velocity (PWV).The book presents a novel approach to the problem of cardiovascular disease, showing it in relation to great vessels disease and revealing a comprehensive approach to the problem of increased rigidity of the great vessels, its causes, and further consequences.Information provided is accompanied by online access to a supplemental website with video clips of anatomic specimens, cardiac imaging, and surgical procedures.Introduces the latest information on early vascular aging (EVA), complete with summaries of recent evidence and guidelines for relevant risk factor controlIdeal reference for the study of vascular aging, pulse wave velocity, arteriosclerosis, EVA, arterial stiffness, vascular, PWV biomarkers, and cardiovascular diseaseContains all the relevant information available from different fields of knowledge (from basic biology to epidemiology) in regard to EVAProvides evidence that leads to a new target for interventions, early vascular aging (EVA) in subjects with early onset increased arterial stiffnessIncludes online access to a supplemental website with video clips of anatomic specimens, cardiac imaging, and surgical procedures

Recenzijas

"... it builds on the evidence in previous chapters, eventually signing off with a discussion of possible means to retard vascular aging...a good start on the expanding field of EVA. Score: 82 - 3 Stars" --Doody's

Papildus informācija

A comprehensive look at early vascular aging (EVA), its link to arterial stiffness, and other age-related changes in the vascular tree
List of Contributors
ix
Preface xi
1 Historical Aspects and Biology of Aging
Peter M. Nilsson
Evolutionary Traits, Genes, and the Environment Influencing Aging
1(1)
Changes During the Twentieth Century in Life Expectancy
2(1)
Early Life Programming Effects
2(1)
Vascular Aging in Perspective
3(1)
New Models and Interventions to Influence Aging
3(1)
Acknowledgment
4(1)
References
4(3)
2 Cellular and Molecular Determinants of Arterial Aging
Patrick Lacolley
Pascal Challande
Veronique Regnault
Edward G. Lakatta
Mingyi Wang
Introduction
7(1)
Cytoskeletal and Contractile Proteins in the Aging Arterial Wall
8(1)
Cellular Matrix Structure in the Aging Arterial Wall
9(1)
Proinflammatory Molecular, Cellular, and Vascular Events in the Aging Arterial Wall
9(3)
Transcription Factors
12(1)
Anti-Inflammatory Molecule SIRT1
12(1)
Conclusion
13(1)
Acknowledgment
13(1)
References
13(4)
3 Aging Population: Challenges and Opportunities in a Life Course Perspective
Angelo Scuteri
Peter M. Nilsson
Aging Populations---Between Decreasing Mortality and Improved Health
17(2)
Living Longer, but with More Chronic Diseases
19(1)
From Healthcare of Older Subjects to Life Course Approach
19(1)
Strategies for Healthy Aging
19(1)
References
20(1)
4 Population-Based Studies: Milestones on the Epidemiological Timeline
Ernst Rietzschel
Pedro G. Cunha
Introduction
21(8)
References
29(4)
5 Lessons from the Amsterdam Growth and Health Longitudinal Study
Isabel Ferreira
Roel J. Van De Laar
AGAHLS---The Cohort Profile
33(3)
Early Determinants of Arterial Stiffness---A Life Course Approach
36(5)
Additional Studies
41(1)
Conclusions
42(1)
Acknowledgment
42(1)
References
42(3)
6 Cardiovascular Aging: Perspectives from the Baltimore Longitudinal Study of Aging (BLSA)
Shweta Shukla
Edward G. Lakatta
Introduction
45(2)
Detecting Occult CV Disease in BLSA Participants
47(1)
Epidemiological Studies of Genetic and Hormonal and Metabolic Risk Factors for CAD
48(1)
Age-Associated Changes in Pulse Wave Velocity (PWV) and the Arterial Waveform
49(7)
Arterial Stiffness as Early Markers for Subsequent CV Events in Asymptomatic BLSA Participants
56(1)
Age-Associated Changes in Carotid Intimal---Medial Thickness
57(2)
The Vascular Aging: The Link that Bridges Age to Early Atherosclerosis (The VALIDATE Study)
59(1)
Arterial---Heart Coupling
59(1)
References
60(5)
7 Changes in Peripheral Blood Pressure with Normal and Accelerated Aging
Stanley S. Franklin
Michael H. Olsen
Introduction
65(1)
What Induces Accelerated Vascular Aging?
65(2)
Changes in Peripheral BP During Normal Aging
67(1)
Changes in Peripheral BP During Accelerated Aging
68(1)
Predictors of Diastolic Hypertension
68(1)
Predictors of ISH in Adolescents and Young Adults
68(1)
Predictors of ISH in Middle-Aged and the Elderly
69(1)
The Value of Paired BP Components in Predicting CVD Risk
69(2)
Perspectives
71(1)
References
72(3)
8 Changes in Arterial Stiffness with Normal and Accelerated Aging
Pierre Boutouyrie
Trine K. Sønder
Introduction
75(1)
A Word of Caution on Study Design
75(1)
Chronological Aging of the Arteries
76(2)
Accelerated Aging of the Arteries
78(3)
Summarizing Remarks
81(1)
References
81(2)
9 Changes in Central Hemodynamics, Wave Reflection, and Heart---Vessel Coupling with Normal and Accelerated Aging
Thomas Weber
Patrick Segers
Introduction
83(1)
The Heart and Its Interaction with the Arterial Tree
83(3)
Aging and Wave Reflections
86(3)
Central Arterial Pressure
89(2)
References
91(6)
10 Early Aging of Endothelial Function and Platelet---Vessel Wall Interactions
Veronique Regnault
Jeremy Lagrange
Patrick Lacolley
Introduction
97(1)
Platelet---Vessel Wall Interactions in Hemostasis
98(1)
Regulation of the Adhesiveness of Platelets at the Vessel Wall
99(1)
Age-Related Changes in Platelet---Vessel Wall Interactions
99(1)
Clinical Implications of Platelet---ECs Interactions and Drug Development
100(1)
References
101(4)
11 The Cross-Talk Between the Macro- and the Microcirculation
Stephane Laurent
Enrico Agabiti-Rosei
Introduction
105(1)
Small Artery in Normal and Accelerated Aging
105(4)
Large-Artery Remodeling
109(2)
Large-/Small-Artery Cross-Talk in Normal and Accelerated Aging
111(4)
Conclusion
115(1)
Acknowledgment
115(1)
References
115(2)
12 Arterial Stiffness and Blood Pressure Variability
Gianfranco Parati
Juan E. Ochoa
Paolo Salvi
Giuseppe Schillaci
Introduction
117(8)
Conclusions
125(1)
References
126(3)
13 Early Vascular Aging in the Young: Influence of Birth Weight and Prematurity
Peter M. Nilsson
Carmel M. McEniery
Introduction
129(1)
Development of the Vasculature During Fetal Life
And Early Childhood
129(1)
Influence of Birth Weight on Blood Pressure
130(1)
Impact of Birth Weight on Vascular Structure and Function
130(2)
Influence of IUGR/SGA Phenotype on Arterial Structure and Function
132(1)
Influence of Prematurity on Arterial Structure and Function
132(1)
Influence of IUGR Versus Prematurity
133(1)
Influence of Extreme Prematurity on Vascular Structure and Function
133(1)
Effects of Increased "Catch-Up" Growth Patterns
134(1)
Summary
134(1)
Acknowledgment
134(1)
References
134(3)
14 Age-Induced Endothelial Dysfunction and Intima---Media Thickening
Michaela Kozakova
Arno Schmidt-Truksass
Age-Induced Endothelial Dysfunction
137(2)
Age-Induced Intima---Media Thickening
139(3)
References
142(5)
15 Glucose Metabolism, Diabetes, and the Arterial Wall
Coen D.A. Stehouwer
Isabel Ferreira
Michaela Kozakova
Carlo Palombo
Hyperglycemia, Insulin Resistance, and Arterial Wall
Damage
147(1)
Preclinical Large Artery Changes in Diabetes Mellitus
148(3)
Preclinical Large Artery Changes in the MetS and Obesity
151(1)
Conclusions
152(1)
References
153(4)
16 Chronic Inflammation and Atherosclerosis
Jan Nilsson
Isabel Goncalves
Andreas Edsfeldt
Age and Development of Atherosclerosis
157(1)
Inflammation and Plaque Formation According to the Response--to--Retention Theory
157(1)
Evidence for the Role of Inflammation in Atherosclerosis
158(2)
The Role of Cytokines and Chemokines
160(2)
Regulation and Resolution of Inflammation
162(1)
Factors Increasing Vascular Aging
163(1)
Inflammation as a Therapeutic Target
164(1)
References
165(4)
17 Early and Late Stages of Chronic Kidney Disease in Relation to Arterial Changes
Panagiotis I. Georgianos
Pantelis A. Sarafidis
Introduction
169(1)
Arterial Stiffness and Wave Reflections
170(1)
Arterial Changes in Early and Predialysis CKD
171(2)
Arterial Changes in Patients with ESRD
173(1)
Pathogenesis of Arterial Stiffness in CKD and ESRD
174(3)
Conclusion
177(1)
References
177(4)
18 Non-Hemodynamic Components of EVA: Polycystic Ovary Syndrome (PCOS)
Irene Lambrinoudaki
Introduction
181(1)
Definition of PCOS
181(1)
PCOS and Risk Factors of Cardiovascular Disease
181(1)
PCOS Phenotypes and Cardiometabolic Risk
182(1)
Subclinical Arterial Disease in Women with PCOS
182(6)
Cardiovascular Disease Outcomes in Women with PCOS
188(3)
Conclusions
191(1)
Acknowledgments
191(1)
References
191(4)
19 Impact of Arterial Aging on Early and Late Stages of Brain Damage
Angelo Scuteri
Stephanie Debette
Cognitive Decline and Dementia: The Emerging Role of Arterial Aging
195(1)
Structural Brain Changes and Arterial Aging
196(1)
Pathophysiological Consideration
196(1)
Therapeutic Opportunities and Research Perspectives
197(1)
Conclusion
198(1)
References
198(3)
20 Telomere Biology and Vascular Aging
Frej Fyhrquist
Peter M. Nilsson
Introduction
201(1)
Telomere Length and Cellular Senescence
201(1)
Telomere Structure and Function
202(1)
Measurement of Telomere Length
203(1)
Regulation of Telomere Length
204(1)
Endogenous Factors
204(1)
Environmental Factors
205(1)
Telomere Length and Vascular Aging and Disease
206(1)
LTL, Cardiovascular Risk Factors, and Cardiac Disease
207(1)
Concluding Remarks
208(1)
Acknowledgment
209(1)
References
209(4)
21 Traditional Versus New Models of Risk Prediction
Thomas Sehestedt
Michael H. Olsen
Evaluating New Risk Models
213(1)
Screening
214(1)
Traditional Risk Models
215(1)
Risk Estimation Using New Markers of Subclinical Organ Damage
215(6)
Future Research
221(1)
References
222(3)
22 Imaging Biomarkers: Carotid Intima-Media Thickness and Aortic Stiffness as Predictors of Cardiovascular Disease
Costas Tsioufis
Charalambos Vlachopoulos
Introduction
225(1)
Carotid Intima---Media Thickness and CV Prognosis
225(5)
Aortic Stiffness and CV Prognosis
230(5)
Conclusion
235(1)
References
235(4)
23 Genetic Markers in Prediction. of Cardiovascular Disease
Kate Witkowska
Meixia Ren
Mark Caulfield
Cardiovascular Disease---What Is the Risk?
239(1)
Familial Syndromes---Monogenic Diseases
239(6)
Complex Diseases---GWAS and the Search for Common Variants
245(2)
Missing Heritability---Limitations of GWAS
247(1)
Building on GWAS---The Future of Cardiovascular Genomics
248(5)
Lessons Learned from GWAS---Biological Mechanisms and Pathways
253(3)
Concluding Remarks
256(1)
References
256(5)
24 Vascular Aging and Cardiovascular Disease
Pedro G. Cunha
Michael H. Olsen
Changes with Age in the Arterial Tree
261(4)
Monitoring Vascular Aging and Detecting Accelerated Signs of Vascular Deterioration
265(2)
Central Hemodynamic Variables and Association to CV Risk
267(1)
Conclusions and Future Perspectives
267(1)
References
268(5)
25 Lifestyle Intervention: What Works?
Charalambos Vlachopoulos
Panagiotis Xaplanteris
Smoking
273(2)
Diet and Nutrition
275(4)
Obesity and Weight Loss
279(1)
Mental, Emotional Status, and Work Stress
279(1)
Exercise
280(1)
Air Pollution
280(1)
Illegal Substances
281(1)
References
281(6)
26 Targeting Blood Pressure Lowering and the Sympathetic Nervous System
Dagmara Hering
Krzysztof Narkiewicz
Tests for Studying the Human Sympathetic Nervous System
287(1)
Role of the Sympathetic Nervous System in Human Hypertension
288(2)
The Link Between the Sympathetic Nervous System and Arterial Stiffening
290(1)
Pharmacological Modulation of Arterial Stiffness
291(1)
Effect of Procedural Interventions on Arterial Stiffness and Sympathetic Outflow
291(1)
Other Device-Based and Interventional Strategies for Lowering BP
292(1)
Baroreceptor Stimulation
292(1)
Deep Brain Stimulation
292(1)
Carotid Body Denervation
292(1)
Device-Guided Slow Breathing
293(1)
Future Directions
293(1)
References
293(4)
27 Targeting Central Blood Pressure Through the Macro- and Microcirculation Cross-Talk
Stephane Laurent
Damiano Rizzoni
Introduction
297(1)
Effects of Drugs on Small Artery Structure and Function in Hypertension
297(2)
Effects of Drugs on Large Artery Structure and Function in Hypertension
299(3)
Targeting Central BP Through the Macro- and Microcirculation Cross-Talk
302(3)
Conclusion
305(1)
References
306(3)
28 Treatment Aspects
PART I Treatment of Abnormalities in Lipid Metabolism and EVA
309(5)
Vasilios Kotsis
What Is Early Vascular Aging (EVA) and How Can It Be Measured?
309(1)
Hyperlipidemia and EVA
310(1)
Treatment of Lipids and EVA
311(1)
Conclusions and Perspectives
312(1)
References
313(1)
PART II Early Vascular Aging and Obesity Treatment
Jens Jordan
314(1)
Obesity and Early Vascular Aging
314(1)
Current Recommendations for Weight Management Do Not Include EVA Biomarkers
315(1)
Obesity Management---Influences on Vascular Aging Biomarkers
315(1)
Summary and Future Outlook
316(1)
References
316(2)
PART III Treatment of Abnormalities in Glucose Metabolism
Carl J. Ostgren
318(1)
Hyperglycemia and Vascular Aging
318(1)
Definition
318(1)
Treatment
319(1)
Treatment Goals for Glycemic Control
319(1)
Lifestyle
320(1)
Oral Agents and Non-Insulin Injectables
320(1)
Metformin
320(1)
Sulfonylurea
320(1)
Thiazolidinediones
320(1)
DPP4 Inhibitors and GLP-1 Receptor Agonists
320(1)
α-Glucosidase Inhibitors
321(1)
SGLT2-Inhibitors
321(1)
Insulin
321(1)
References
321(2)
29 New Drugs Under Development for Cardiovascular Prevention
Stephane Laurent
Ulrike M. Steckelings
Introduction
323(1)
New Molecules Targeting Isolated Systolic Hypertension
323(2)
New Drugs for Hypertension
325(6)
Other Possible Alternatives to Classical Drugs
331(1)
Conclusion
331(1)
References
332(3)
30 Interventions to Retard Biological Aging to Be Explored
Tine De Backer
Pierre Boutouyrie
Luc Van Bortel
Introduction
335(1)
Vascular Aging
335(2)
Preventable Factors Leading to EVA
337(2)
Progeria: A Model of Extreme EVA
339(1)
Skin Aging
340(1)
Bone Aging
341(2)
Conclusion
343(1)
References
343(4)
31 Immunization, Vaccines, and Immunomodulation
Yimin Lu
Michel Burnier
Introduction
347(1)
Defining the Target for Immunization and Role of Immunity in Hypertension
348(1)
Immunization
348(1)
Renin Immunization
349(1)
Angiotensin I (Ang I) Vaccine
350(1)
Ang II Vaccine
351(1)
ATIR Vaccine
352(1)
Safety of Anti-RAAS Vaccines
353(2)
References
355(2)
Index 357
Michael Hecht Olsen is a professor in Hypertension and Cardiovascular Prevention at the Department for Regional Health Research, University of Southern Denmark, and senior consultant in cardiology at Department of Medicine 1, Holbaek Hospital, Denmark.

Both clinically and in research, he works with hypertension, obesity, diabetes and cardiovascular risk stratification using measurements of subclinical cardiovascular damage (e.g., pulse wave analysis, ultrasound of the carotid arteries and echocardiography) and new biomarkers for deep phenotyping trying to develop individualized treatment. He has published over 200 publications (Web of Science H-index 47).

Peter M. Nilsson is Senior Professor/expert in Clinical Cardiovascular Research at Lund University, Department of Clinical Sciences, Skåne University Hospital, Malmö, Sweden. For many years he has been developing the concept of EVA with numerous colleagues and the prevention of cardiovascular disease and type 2 diabetes.

Stepane Laurents research interests are hypertension pathophysiology and management, pharmacology of antihypertensive drugs, arterial stiffness and vascular ageing. He has served as President of the European Society of Hypertension (ESH) (2007-2009) and President of the ARTERY Society (2010-2012), and is the author of over 500 referenced articles and 20 chapters in books.